Thai Agencies Urge Delay Of H1N1 Vaccine Trials As Virus Seed Mutates
This article was originally published in PharmAsia News
Executive Summary
Thailand's health agencies within the Ministry of Public Health have concluded clinical trials for a locally made H1N1 flu vaccine should be delayed because the seed virus has mutated. A university professor found the virus strain obtained from Russia had mutated and thus was unstable and unsuited for production. The professor said health agencies agreed to recommend the MPH ethics committee halt trials of the Russian seed virus, but allow trials to proceed using a separate seed virus obtained from China. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.